Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.

Veitonmäki, Niina ; Hansson, Markus LU orcid ; Zhan, Fenghuang ; Sundberg, Annika ; Löfstedt, Tobias LU ; Ljungars, Anne ; Li, Zhan-Chun ; Martinsson-Niskanen, Titti ; Zeng, Ming and Yang, Ye , et al. (2013) In Cancer Cell 23(4). p.502-515
Abstract
We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival compared to... (More)
We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival compared to currently used treatments in advanced experimental models of multiple myeloma. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Cell
volume
23
issue
4
pages
502 - 515
publisher
Cell Press
external identifiers
  • wos:000317943900010
  • pmid:23597564
  • scopus:84876385896
  • pmid:23597564
ISSN
1878-3686
DOI
10.1016/j.ccr.2013.02.026
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Tumour Biology, Malmö (013031300), Faculty of Medicine (000022000), Medical Inflammation Research (013212019), Oncology, MV (013035000) Department affilation moved from v1000588 (Tumour Biology, Malmö) to v1000562 (Department of Translational Medicine) on 2016-01-18 14:39:29.
id
5f8f17c9-2f57-44fa-9d32-096b5e674101 (old id 3733600)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23597564?dopt=Abstract
date added to LUP
2016-04-01 11:00:04
date last changed
2024-10-21 19:48:34
@article{5f8f17c9-2f57-44fa-9d32-096b5e674101,
  abstract     = {{We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target in cancer. The BI-505 epitope was strongly expressed on the surface of multiple myeloma cells from both newly diagnosed and relapsed patients. BI-505 had potent macrophage-dependent antimyeloma activity and conferred enhanced survival compared to currently used treatments in advanced experimental models of multiple myeloma.}},
  author       = {{Veitonmäki, Niina and Hansson, Markus and Zhan, Fenghuang and Sundberg, Annika and Löfstedt, Tobias and Ljungars, Anne and Li, Zhan-Chun and Martinsson-Niskanen, Titti and Zeng, Ming and Yang, Ye and Danielsson, Lena and Kovacek, Mathilda and Lundqvist, Andrea and Mårtensson, Linda and Teige, Ingrid and Tricot, Guido and Frendéus, Björn}},
  issn         = {{1878-3686}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{502--515}},
  publisher    = {{Cell Press}},
  series       = {{Cancer Cell}},
  title        = {{A human icam-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.}},
  url          = {{http://dx.doi.org/10.1016/j.ccr.2013.02.026}},
  doi          = {{10.1016/j.ccr.2013.02.026}},
  volume       = {{23}},
  year         = {{2013}},
}